Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Missouri for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Missouri only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Missouri (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Andrew Iliff (NPI 1851654818)

Field	Value
Entity Type	Individual
Organization	Andrew Iliff
Address	1705 E Broadway Ste 100
City	Columbia
State	MO
ZIP	65201
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	June 24, 2012

Payer Source	Total Paid
Medicare	$2.8M
Medicaid	$0

Key Findings

This provider’s Medicare footprint is concentrated and material: lifetime Medicare revenue is $2.8M and there is no Medicaid billing on file, so the practice is effectively single‑payer from a public-program perspective and relies on Medicare for its publicly reported volume and revenue. The absence of Medicaid activity may affect access to dual‑eligible or low‑income populations and suggests limited engagement with state Medicaid programs.

Revenue is heavily concentrated in a small set of high-cost oncology drugs: the top 3 Medicare codes (J9271, J9299, J9144) together account for 56.5% of the provider’s total Medicare revenue. Individually, J9271 contributes 30.9% of Medicare revenue, J9299 contributes 13.5%, and J9144 contributes 12.0%, indicating that immunotherapy and targeted oncology injectables drive the majority of billed Medicare dollars.

The clinical and operational profile implied by the code mix is a medical oncology practice with on-site infusion capabilities: high revenue from J9271 (pembrolizumab), J9299 (nivolumab), and J9144 (daratumumab), combined with chemotherapy administration codes such as 96413 and supportive drugs like J2506 and J1568, point to routine in‑office infusion of biologics and systemic cancer therapies. This mix suggests the practice treats both solid tumors (checkpoint inhibitors) and hematologic disease (daratumumab), and manages infusion logistics and drug acquisition.

Competitive standing across top oncology drugs is generally modest rather than dominant. For J9271 the provider ranks #439 of 1841 (76th percentile; typical, unremarkable volume), for J9299 it ranks #244 of 505 (52th percentile; typical, unremarkable volume), and for J9144 it ranks #290 of 615 (52th percentile; typical, unremarkable volume), which together indicate middle‑tier national activity for these agents rather than leadership.

There are notable relative strengths and weaknesses in specific codes that inform competitive posture: the provider’s J0881 activity (41.7K claims, $83.3K revenue) ranks #102 of 1114 (91th percentile; typical, unremarkable volume), signaling comparatively high participation with darbepoetin alfa, whereas J9173 (durvalumab) ranks #45 of 53 (15th percentile; typical, unremarkable volume), indicating limited use of that agent. These differences suggest selective prescribing patterns or patient-mix effects across different oncology and supportive care drugs.

Office visit volume for established patients is an outlier versus national peers: code 99214 has 1.3K claims and $115.5K revenue (4.3% of Medicare revenue) and ranks #5897 of 479517 (99th percentile; extreme outlier, far above typical national volume for this code). This extreme standing for 99214 implies a high intensity of outpatient management and follow‑up in Medicare beneficiaries relative to most providers, which may reflect ongoing chronic oncology care, frequent follow‑up visits, or coding intensity patterns.

The presence of imaging and multiple infusion administration codes supports an integrated outpatient oncology operation: 78815 (PET/CT) generates $78.3K (2.9% of Medicare revenue) and ranks #2637 of 6566 (59th percentile; typical, unremarkable volume), while chemotherapy administration codes such as 96413 (532 claims, $48.4K) and additional infusion codes (96365, 96367) appear on the revenue list. Together these items indicate that the practice bills for diagnostic imaging and delivers infusions in the outpatient setting rather than solely providing consultative services.

The provider has an established billing history with long tenure: the NPI was enumerated 2012-06-24 (~14 years ago), which combined with lifetime Medicare revenue of $2.8M suggests a steady, mid‑sized Medicare oncology practice over time. Given the lack of Medicaid billing on file, growth or risk strategies that rely on expanding Medicaid-covered volume would require new payer relationships or affiliation changes.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

69 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	19,200	$40	$825.6K
J9299	Injection, nivolumab, 1 mg	15,020	$20	$360.5K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	8,460	$40	$321.5K
J0897	Injection, denosumab, 1 mg	12,720	$20	$241.7K
J9173	Injection, durvalumab, 10 mg	2,400	$60	$148.8K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	4,010	$30	$136.3K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,280	$90	$115.5K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	41,670	$1	$83.3K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	80	$1,030	$78.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	530	$90	$48.4K

Showing 1–10 of 69

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 69 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Missouri Distribution

Andrew Iliff — 3 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Missouri

Full comparison — all codes billed, vs. state median

69 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	8	40	9,100	$40	$502K
J9299	9	20	14,170	$20	$360.3K
J9144	9	20	7,200	$40	$308.4K
J9173	3	10	3,820	$60	$215.9K
J1568	1	10	2,900	$30	$103.8K
J0897	15	210	2,400	$20	$82.4K
J0881	5	10	15,500	$1	$63.1K
J1437	5	10	2,500	$20	$43.5K
Q5116	3	10	1,840	$20	$36.9K
J0641	2	10	35,150	$1	$27.3K

Showing 1–10 of 69

Related Providers

Other providers that share a Tax Identification Number (TIN) with Andrew Iliff, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Liana Makarian	MO	Hematology & Oncology Physician	$3.3M	$0
Umasankar Ramadoss	MO	Hematology & Oncology Physician	$3.3M	$0
Mark Tungesvik	MO	Hematology & Oncology Physician	$3.3M	$0
Elangovan Balakrishnan	MO	Hematology & Oncology Physician	$3.1M	$0
Mudappa Kalaiah	IA	Rheumatology Physician	$652.3K	$0
Mark Bryer	MO	Radiation Oncology Physician	$638K	$0
Aneley Hundae	FL	Cardiovascular Disease Physician	$604.9K	$0
Reed Cope	MO	Radiation Oncology Physician	$572.2K	$0
Alexandre Tungesvik	MO	Hematology & Oncology Physician	$569.8K	$0
Harold Johnson	MO	Radiation Oncology Physician	$542.5K	$0

Nearby Providers

Other providers in the same ZIP code as Andrew Iliff, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Woodhaven	MO	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$88.3M
Palmer's Home Care, LLC	MO	Intellectual and/or Developmental Disabilities Residential Treatment Facility	$0	$82.3M
Oats, Inc.	MO	Non-emergency Medical Transport (VAN)	$0	$23.4M
Independent Living Center Of Mid-missouri Inc.	MO	Specialist	$0	$14.2M
Ch Allied Services, Inc.	MO	General Acute Care Hospital	$0	$8.6M
Central Missouri Area Agency On Aging	MO	Voluntary or Charitable Agency	$0	$8.4M
Life Christain Outreach	MO	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$7.1M
Surgical Center At Columbia Orthopaedic Group LLC	MO	Ambulatory Surgical Clinic/Center	$6.2M	$0
Mid-missouri Supported Living	MO	Intellectual and/or Developmental Disabilities Residential Treatment Facility	$0	$5.3M
Woodhaven Learning Center	MO	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$5.1M

Andrew Iliff — Billing Profile & Reimbursement Data

Sign up for Andrew Iliff — Billing Profile & Reimbursement Data policy alerts

Andrew Iliff — Billing Profile & Reimbursement Data

Sign up for Andrew Iliff — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References